Celltrion treatment clinical presentation “No side effects and reduced treatment period by 6.4 days”

Celltrion’s new coronavirus infection (Corona 19) antibody treatment, which is being developed by Celltrion, shortens the treatment period for some patients with Corona 19, according to a study.

On the 13th, the results of the phase 2 clinical trial of Celltrion’s COVID-19 treatment (Rekironaju) were revealed. Joong-shik Um, a professor of infectious medicine at Gachon University Gil Hospital, announced the treatment effect of Rekkirona at the’High1 New Drug Development Symposium’ hosted by the Korean Pharmacy Society at 6 pm.

According to Professor Um’s presentation of a clinical trial of Rekirona, Celltrion’s antibody therapy was particularly effective in moderately ill patients with pneumonia or over 50 years of age.

It took 6.6 days to recover clinically for patients with moderate illness over 50 years of age, but took 13 days for a placebo (a fake drug). Rekironaju shortened the treatment period by 6.4 days.

In addition, in the case of moderate Corona 19 patients with pneumonia, recovery after 5.7 days after receiving recyrona injection, but otherwise, it took 10.8 days to recover.

All Corona 19 patients who participated in this clinical trial recovered from Corona 19 after an average of 8.8 days after injection of placebo, and those who received the Rekirona injection were clinically treated for Corona 19 after 5.4 days, which was 3.4 days shorter than this.

The researchers also found that the reduction of the Corona 19 virus in the body was also accelerated by administering Rekirona. Compared to the placebo administration, the virus concentration was significantly lowered 7 days after administration of Rekironaju.

Professor Um Joong-sik said in a presentation, “Rekkironaju can shorten the hospitalization period for patients with Corona 19 by up to a week or more, so the hospital bed operation will be breathless.”

The researchers found that the safety evaluation of Rekyronaju was also satisfactory in phase 2 clinical trials. No serious adverse reactions or deaths occurred among corona19 patients who were injected with Rekirona.

Rekironaju is currently the only treatment that has reached the approval stage after obtaining approval for a clinical trial by the Ministry of Food and Drug Safety among the COVID-19 treatments developed in Korea. The results of this study were published in Nature Communications, a sister magazine of Nature, the world’s top three academic journals.

However, the results of this study are not related to the treatment of severely ill patients with Corona 19. Corona 19 patients are divided into ▶ mild patients who do not require hospitalization ▶ moderate patients who need oxygen mask treatment ▶ severe patients who need intensive care unit (ICU) treatment or equipped with a ventilator. Celltrion’s antibody treatment was conducted in phase 2 clinical trials for 307 mild and moderate corona19 patients.

Reporter Choi Jun-ho and Moon Hee-cheol [email protected]